Connection

MANDEEP BAJAJ to Signal Transduction

This is a "connection" page, showing publications MANDEEP BAJAJ has written about Signal Transduction.
Connection Strength

0.268
  1. The regulation of muscle protein turnover in diabetes. Int J Biochem Cell Biol. 2013 Oct; 45(10):2239-44.
    View in: PubMed
    Score: 0.046
  2. Myocardial protection against ischemia-reperfusion injury by GLP-1: molecular mechanisms. Metab Syndr Relat Disord. 2012 Dec; 10(6):387-90.
    View in: PubMed
    Score: 0.043
  3. Discordant effects of a chronic physiological increase in plasma FFA on insulin signaling in healthy subjects with or without a family history of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Sep; 287(3):E537-46.
    View in: PubMed
    Score: 0.024
  4. Metabolic and molecular basis of insulin resistance. J Nucl Cardiol. 2003 May-Jun; 10(3):311-23.
    View in: PubMed
    Score: 0.023
  5. Acupuncture Reduces Hypertrophy and Cardiac Fibrosis, and Improves Heart Function in Mice with Diabetic Cardiomyopathy. Cardiovasc Drugs Ther. 2020 12; 34(6):835-848.
    View in: PubMed
    Score: 0.019
  6. DPP-4 inhibition by linagliptin prevents cardiac dysfunction and inflammation by targeting the Nlrp3/ASC inflammasome. Basic Res Cardiol. 2019 08 06; 114(5):35.
    View in: PubMed
    Score: 0.017
  7. Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovasc Drugs Ther. 2018 04; 32(2):135-145.
    View in: PubMed
    Score: 0.016
  8. GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials. Cardiovasc Drugs Ther. 2018 02; 32(1):65-72.
    View in: PubMed
    Score: 0.016
  9. SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor. Cardiovasc Drugs Ther. 2017 Apr; 31(2):119-132.
    View in: PubMed
    Score: 0.015
  10. Aleglitazar, a dual peroxisome proliferator-activated receptor-a and -? agonist, protects cardiomyocytes against the adverse effects of hyperglycaemia. Diab Vasc Dis Res. 2017 03; 14(2):152-162.
    View in: PubMed
    Score: 0.015
  11. Aleglitazar, a Balanced Dual PPARa and -? Agonist, Protects the Heart Against Ischemia-Reperfusion Injury. Cardiovasc Drugs Ther. 2016 Apr; 30(2):129-41.
    View in: PubMed
    Score: 0.014
  12. Dickkopf-1 (DKK1) phosphatase and tensin homolog on chromosome 10 (PTEN) crosstalk via microRNA interference in the diabetic heart. Basic Res Cardiol. 2013 May; 108(3):352.
    View in: PubMed
    Score: 0.011
  13. Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol. 2013 Jan 01; 304(1):H131-41.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.